Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program

Qi Shen,Zijun Y. Xu-Monette,Ganiraju C. Manyam,Carlo Visco,Alexander Tzankov,Xin Cao,Lijuan Deng,Santiago Montes-Moreno,Karen Dybkær,April Chiu,Attilio Orazi,Youli Zu,Govind Bhagat,Kristy L. Richards,Eric D. Hsi,William W.L. Choi,J. Han van Krieken,Jooryung Huh,Maurilio Ponzoni,Andrés J.M. Ferreri,John P. Farnen,Michael Boe Møller,Jane N. Winter,Miguel A. Piris,L. Jeffrey Medeiros,Ken H. Young

Akt activation confers an inferior survival in patients with activated B-cell subtype of diffuse large B-cell lymphoma: a report from The International DLBCL Rituximab-CHOP Consortium Program

2015

S220 510 EZH2-Activating Mutations in DLBCL Are Easily Predictable by Routine Immunohistochemistry Analysis: a Tool to More Efficiently Define EZH2 Inhibitor-Sensitive Patients? Sydney Dubois, Sylvain Mareschal, Marie Cornic, Jean-Michel Picquenot, Elodie Bohers, Marion Alcantara, Catherine Maingonnat, Philippe Bertrand, Philippe Ruminy, Christian Bastard, Herve Tilly, Fabrice Jardin INSERM U918, Centre Henri Becquerel

Keywords:

Rituximab
Becquerel
Immunology
Diffuse large B-cell lymphoma
Pathology
Protein kinase B
CHOP
B cell
Medicine
EZH2
Immunohistochemistry
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations